(Q38741675)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

review article

1 reference

title

A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

chronic renal insufficiency

22 March 2020

main subject

1 reference

Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

inferred from title

corrigendum / erratum

0 references

author

Wendy St Peter

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Eric Weinhandl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Katie E Cardone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Lori D Wazny

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Joanna Q Hudson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

publication date

1 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

1155-1186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28584909%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-017-0758-5

22 March 2020

exact match

0 references

cites work

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Serum phosphorus levels associate with coronary atherosclerosis in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Serum phosphate and mortality in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Elevated serum phosphate predicts mortality in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

The extra-phosphate intestinal load from medications: is it a real concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A dearth of data: the problem of phosphorus in prescription medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Network meta-analysis-highly attractive but more methodological research is needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Calculating the number needed to treat for trials where the outcome is time to an event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Design and baseline characteristics of the LANDMARK study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Reasons for phosphate binder discontinuation vary by binder type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

The phosphate binder equivalent dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Management of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Does good medication adherence really save payers money?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Industry sponsored bias in cost effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Nicotinamide and phosphate homeostasis in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0758-5

Efficacy and safety of SBR759, a new iron-based phosphate binder

21 January 2018

1 reference

12 December 2020

The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis

1 reference

12 December 2020

Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease

1 reference

12 December 2020

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5

1 reference

12 December 2020

Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review

1 reference

12 December 2020

JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients

1 reference

12 December 2020

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis

1 reference

12 December 2020

Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients

1 reference

12 December 2020

A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice

1 reference

12 December 2020

Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control

1 reference

12 December 2020

Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer

1 reference

12 December 2020

Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency

1 reference

12 December 2020

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model

1 reference

12 December 2020

Reduction of costs for anemia-management drugs associated with the use of ferric citrate

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease

1 reference

12 December 2020

Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease

1 reference

12 December 2020

Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia

1 reference

12 December 2020

Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease

1 reference

12 December 2020

Serum calcium, phosphorus and cardiovascular events in post-menopausal women

1 reference

12 December 2020

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

1 reference

12 December 2020

The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients

1 reference

12 December 2020

Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride

1 reference

12 December 2020

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

1 reference

12 December 2020

RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers

1 reference

12 December 2020

Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation

1 reference

12 December 2020